Inclusion Criteria

Patients may be eligible for this trial if they:

• Are HIV-positive.
• Have HIV levels of 10,000 copies/ml or more.
• Are between ages 4 and 22.
• Have motivation and ability to conform to the complex treatment regimen.
• Agree to practice abstinence or use 2 effective methods of birth control during the study and until 3 months after stopping the study drugs, if sexually active.
• Have written informed consent from a parent or legal guardian if under age 18.
• Have used at least 3 different nucleoside reverse transcriptase inhibitors (NRTIs) for at least 3 months each or have shown resistance to at least 3 different NRTIs.
• Have used at least 1 nonnucleoside reverse transcriptase inhibitor (NNRTI) for at least 3 months each or have shown resistance.
• Have used at least 2 different courses of a protease inhibitor (PI)-containing regimen, each of which was at least 6 months, or have evidence of mutations to at least 2 different PIs.
• This study has been changed. The inclusion criteria reflects a change in the prior anti-HIV therapy required, age requirement, and the required CD4 and HIV levels.

Exclusion Criteria

Patients will not be eligible for this trial if they:

• Are allergic to even 1 study drug or have ever had to stop 1 of these drugs because of a bad reaction to it.
• Have a history of diabetes, hepatitis C, hepatitis B, or certain diseases of the nervous system, heart, or pancreas.
• Have had a serious infection within 14 days of starting the study.
• Need certain drugs that interact with the study drugs. (See Technical Summary for more details.)
• Are pregnant or breast-feeding.
• Have had hepatitis within 30 days of study entry.